Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Express Scripts
Baxter
Harvard Business School
McKesson

Last Updated: October 13, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,858,409

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,858,409
Title: Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
Abstract:Compounds are disclosed having the general formula R.sub.1 --X--R.sub.2, wherein R.sub.1 and R.sub.2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R.sub.1 and R.sub.2 may be the same or different. Preferred R.sub.1 and R.sub.2 groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.
Inventor(s): Thompson; Robert C. (Boulder, CO), Hannum; Charles H. (Sunnyvale, CA), Eisenberg; Stephen P. (Boulder, CO), Arend; William P. (Denver, CO), Joslin; Fenneke G. (Denver, CO), Sommer; Andreas (Danville, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO)
Application Number:08/482,283
Patent Claims:1. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding an interleukin-1 inhibitor (IL-1i) polypeptide, having interleukin-1 (IL-1) inhibitory activity, wherein said polypeptide is selected from the group consisting of: A) a polypeptide comprising all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P; and B) a polypeptide that is at least about 70% homologous to the amino acid sequence set forth in A).

2. A nucleic acid molecule of claim 1, wherein the nucleic acid sequence encodes a oolypeptide that is at least 80% homologous to amino acid sequence set forth in claim 1 (A).

3. A nucleic acid molecule of claim 1, wherein the nucleic acid sequence encodes a polypeptide that is at least 95% homologous to amino acid sequence set forth in claim 1 (A).

4. A nucleic acid molecule of claim 1, wherein the nucleic acid sequence encodes a polypeptide wherein (U) is M.

5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding an interleukin-1 inhibitor (IL-1i) polypeptide, having interleukin-1 (IL-1 inhibitoty activity, wherein said polypeptide is selected from the group consisting of: A) a polypeptide comprising all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P; and B) a polypeptide that is at least about 90% homologous to the amino acid sequence set forth in A).

6. The nucleic acid molecule of claim 5, wherein the amino acid sequence of said polypeptide is at least about 90% homologous to the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R.

7. The nucleic acid molecule of claim 6, wherein (U) is nothing.

8. The nucleic acid molecule of claim 6, wherein (U) is M.

9. The nucleic acid molecule of claim 5, wherein the amino acid sequence of said polypeptide is at least about 95% homologous to the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q s P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R.

10. The nucleic acid molecule of claim 5, wherein said polypeptide comprises all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P.

11. The nucleic acid molecule of claim 10, wherein (X) is R.

12. The nucleic acid mnolecule of claim 10, wherein said polypeptide comprises the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P.

13. The nucleic acid molecule of claim 12, wherein (X) is R.

14. The nucleic acid molecule of claim 13, wherein (U) is M.

15. The nucleic acid molecule of claim 13, wherein (U) is nothing.

16. The nucleic acid molecule of claim 13, wherein said polypeptide consists of the following amino acid sequence: (U) R P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E C V M V T K F Y Q E D E wherein (U) is M or nothing.

17. The nucleic acid molecule of claim 16, wherein (U) is M.

18. The nucleic acid molecule of claim 13, wherein said nucleic acid sequence encoding said IL-1i polypeptide further comprises a sequence encoding an N-terminal secretion leader sequence.

19. The nucleic acid molecule of claim 18, wherein the leader sequence comprises all or part of the following amino acid sequence: M E I C R G L R S H L I T L L L F L F H S E T I C.

20. A recombinant host cell containing a DNA molecule comprising a nucleic acid sequence encoding an interleukin-1 inhibitor (IL-1i) polypeptide, said polypeptide being capable of inhibiting IL-1, wherein said polypeptide is selected from the group consisting of A) a polypeptide comprising all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S G R K S S K M O A F R I W D V N O K T F Y L R N N O L V A G Y L O G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L O L E A V N I T D L S E N R K O D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D O P V S L T N M P D E G V M V T K F Y F O E D E wherein (U) is M or nothing and (X) is R or P; and B) a polypeptide that is at least about 70% homologous to the amino acid sequence set forth in A).

21. A recombinant host cell of claim 20, wherein said polypeptide is selected from the group consisting of: A) a polypeptide comprising all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S C R K S S K M Q A P R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P; and B) a polypeptide that is at least about 90% homologous to the amino acid sequence set forth in A).

22. The recombinant host cell of claim 21, wherein the amino acid sequence of said polypeptide is at least about 95% homologous to the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K H C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R.

23. The recombinant host cell of claim 21, wherein the amino acid sequence of said polypeptide is at least about 90% homologous to the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R.

24. The recombinant host cell of claim 23, wherein said host cell is not capable of glycosylation or is a non-human host cell.

25. The recombinant host cell of claim 24, wherein said host cell is selected from a yeast cell, a mouse Ltk.sup.- cell, and a Chinese hamster ovary cell.

26. The recombinant host cell of claim 24, wherein said host cell is a prokaryotic cell.

27. The recombinant host cell of claim 26, wherein said host cell is E. coil.

28. The recombinant host cell of claim 24, wherein said host cell is a eukaryotic cell.

29. The recombinant host cell of claim 28, wherein said host cell is a mammallan cell.

30. The recombinant host cell of claim 28, wherein said host cell is a Chinese hamster ovary cell.

31. The recombinant host cell of claim 23, wherein said host cell produces glycosylated IL-1i.

32. The recombinant host call of claim 23, wherein said host cell produces nonglycosylated IL-1i.

33. The recombinant host cell of claim 23, wherein (U) is nothing.

34. The recombinant host cell of claim 23, wherein (U) is M.

35. The recombinant host cell of claim 21, wherein said polypeptide comprises all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R X Q D K H F A F I R S D E G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E Wherein (U) is M or nothing and (X) is R or P.

36. The recombinant host call of claim 35, wherein (X) is R.

37. The recombinant host cell of claim 35, wherein said polypeptide comprises the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P.

38. The recombinant host cell of claim 37, wherein (X) is R.

39. The recombinant host cell of claim 38, wherein (U) is M.

40. The recombinant host cell of claim 38, wherein (U) is nothing.

41. The recombinant host cell of claim 38, wherein said host cell is not capable of glycosylation or is a non-human host cell.

42. The recombinant host cell of claim 41, wherein said host cell is selected from a yeast cell, a mouse Ltk.sup.- cell, and a Chinese hamster ovary cell.

43. The recombinant host cell of claim 41, wherein said host cell is a prokaryotic cell.

44. The recombinant host call of claim 43, wherein said host cell is E. coli.

45. The recombinant host cell of claim 41, wherein said host cell is a eukaryotic cell.

46. The recombinant host cell of claim 45, wherein said host cell is a mammalian cell.

47. The recombinant host cell of claim 45, wherein said host cell is a Chinese hamster ovary cell.

48. The recombinant host cell of claim 38, wherein said host cell produces glycosylated IL-1i.

49. The recombinant host cell of claim 38, wherein said host cell produces nonglycosylated IL-1 i.

50. The recombinant host cell of claim 38, wherein said DNA molecule comprises a heterologous promoter operatively linked to said nucleic acid sequence encoding said IL-1i polypeptide.

51. The recombinant host cell of claim 38, wherein said nucleic acid sequence encoding said IL-1i polypeptide further comprises a sequence encoding an N-terminal secretion leader sequence.

52. The recombinant host cell of claim 51, wherein the leader sequence comprises all or part of the following amino acid sequence: M E I C R G L R S H L I T L L L F L F H S E T I C.

53. The recombinant host cell of claim 38, wherein said polypeptide consists of the following amino acid sequence: (U) R P S G R K S S K M Q A E R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing.

54. The recombinant host cell of claim 53, wherein (U) is M.

55. The recombinant host cell of claim 54, wherein said host call produces nonglycosylated IL-1i.

56. The recombinant host cell of claim 55, wherein said host cell is E. coli.

57. The recombinant host cell of claim 53, wherein said host cell is a Chinese hamster ovary host cell.

58. The recombinant host cell of claim 53, wherein said host cell is a eukaryotic host cell.

59. The recombinant host cell of claim 53, wherein said host cell produces glycosylated IL-1i.

60. The recombinant host cell of claim 53, wherein said host cell is a mammalian host cell.

61. The recombinant host cell of claim 53, wherein said host cell is a prokaryotic host cell.

62. A process for preparing an interleukin-1 inhibitor (IL-1i) polypeptide, comprising producing the recombinant IL-1i polypeptide in a host cell according to claim 20 under suitable conditions to express the recombinant DNA molecule contained therein to produce the recombinant polypeptide.

63. The process of claim 62, further comprising harvesting the IL-1i polypeptide.

64. A process of claim 63, wherein said recombinant polypeptide is selected from the group consisting of: A) a potypeptide comprising all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P; and B) a polypeptide that is at least about 90% homologous to the amino acid sequence set forth in A).

65. The process of claim 64, wherein the amino acid sequence of said recombinant polypeptide is at least about 95% homologous to the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P T E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R.

66. The process of claim 64, wherein the amino acid sequence of said recombinant polypeptide is at least about 90% homologous to the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I P S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R.

67. The process of claim 66, wherein said host cell is not capable of glycosylation or is a non-human host cell.

68. The process of claim 67, wherein said host cell is selected from a yeast cell, a mouse Ltk.sup.+ cell, and a Chinese hamster ovary cell.

69. The process of claim 67, wherein said host cell is a prokaryotic cell.

70. The process of claim 69, wherein said host cell is E. coli.

71. The process of claim 67, wherein said host cell is a eukaryotic cell.

72. The process of claim 71, wherein said host cell is a mammalian cell.

73. The process of claim 71, wherein said host cell is a Chinese hamster ovary cell.

74. The process of claim 66, wherein said recombinant polypeptide is glycosylated.

75. The process of claim 66, wherein said recombinant polypeptide is nonglycosylated.

76. The process of claim 66, wherein (U) is nothing.

77. The process of claim 66, wherein (U) is M.

78. The process of claim 64, wherein said recombinant polypeptide comprises all or an IL-1 inhibitory fragment of the amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S 0 S G e T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P.

79. The process of claim 78, wherein (X) is R.

80. The process of claim 79, wherein said recombinant polypeptide inhibits IL-1 induced PGE.sub.2 production.

81. The process of claim 78, wherein said recombinant polypeptide comprises the following amino acid sequence: (U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R K Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing and (X) is R or P.

82. The process of claim 81, wherein (X) is R.

83. The process of claim 82, wherein (U) is M.

84. The process of claim 82, wherein (U) is nothing.

85. The process of claim 82, wherein said host cell is not capable of glycosylalion or is a non-human host cell.

86. The process of claim 85, wherein said host cell is selected from a yeast cell, a mouse Ltk.sup.- cell, and a Chinese hamster ovary cell.

87. The process of claim 85, wherein said host cell is a prokaryotic cell.

88. The process of claim 85, wherein said host cell is E. coli.

89. The process of claim 85, wherein said host cell is a eukaryotic cell.

90. The process of claim 89, wherein said host cell is a mammalian cell.

91. The process of claim 89, wherein said host cell is a Chinese hamster ovary cell.

92. The process of claim 82, wherein said recombinant polypeptide is glycosylated.

93. The process of claim 82, wherein said recombinant polypeptide is nonglycosylated.

94. The process of claim 82, wherein said DNA molecule comprises a heterologous promoter operatively linked to said nucleic acid sequence encoding said IL-1i polypeptide.

95. The process of claim 82, wherein said nucleic acid sequence encoding said IL-1i polypeptide further comprises a sequence encoding an N-terminal secretion leader sequence.

96. The process of claim 95, wherein the leader sequence comprises all or part of the following amino acid sequence: M E I C R G L R S H L I T L L L F L F H S E T I C.

97. The process of claim 82, wherein said recombinant polypeptide consists of the following amino acid sequence: (U) R P S G R K S S K M Q A F R I W D V N Q K T F Y L R N N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A L F L G I H G G K M C L S C V K S G D E T R L Q L E A V N I T D L S E N R X Q D K R F A F I R S D S G P T T S F E S A A C P G W F L C T A M E A D Q P V S L T N M P D E G V M V T K F Y F Q E D E wherein (U) is M or nothing.

98. The process of claim 97, wherein (U) is M.

99. The process of claim 98, wherein said recombinant polypeptide is nonglycosylated.

100. The process of claim 99, wherein said host cell is E. coli.

101. The process of claim 97, wherein said host cell is a Chinese hamster ovary host cell.

102. The process of claim 97, wherein said host cell is a eukaryotic host cell.

103. The process of claim 97, wherein said recombinant polypeptide is glycosylated.

104. The process of claim 97, wherein said host cell is a mammalian host cell.

105. The process of claim 97, wherein said host cell is a prokaryotic host cell.

Details for Patent 6,858,409

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   See Pricing Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2022-02-22 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   See Pricing Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2022-02-22 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 003 2001-11-14   See Pricing Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2022-02-22 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 6,858,409

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Dow
Express Scripts
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.